Neutualization of these two inflammasomes released products, IL-1β and IL-18, has been suggested to be a promising therapeutic agent for tumor suppression in certain cancer types [29], indicating the importance of these two cytokines in the tumor microenvironment. The gene discussed is IL1B; the disease is neoplasm.